Atossa Therapeutics (NASDAQ:ATOS) has contracted
with NYC Health + Hospitals/Metropolitan in New York City to conduct
the NY HOPE Study of Atossa’s combination drug therapy called AT-H201.
The study will evaluate AT-H201 in COVID-19 patients on ventilators with
the goal of reducing the amount of time on ventilators.
The primary objectives are to determine the number
of ventilator-free days after patients are removed from ventilators
following the initial airway intervention; oxygenation levels; and
survival rates.
Secondary efficacy endpoints include a variety of lung function parameters and time in ICU.
Atossa has filed comprehensive provisional patent applications related to AT-H201.
https://seekingalpha.com/news/3564592-atossa-up-13-premarket-on-planned-covidminus-19-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.